Entity
  • Rheos Medicines

    Created in 2018
  • BETA

    To investigate (B)
    Some signals may appear as inconsistent with a regular activity
  • Social networks

    287 4,740
  • Activities

  • Technologies

  • Entity types

  • Location

    245 First St, Cambridge, MA 02142, USA

    Cambridge

    United States of America

  • Employees

    Scale: 11-50

    Estimated: 23

  • Engaged corporates

    1
    0 1
  • Added in Motherbase

    5 years, 5 months ago
Description
  • Value proposition

    [Automatic translation follows] Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop a novel class of medicines with potential to transform the lives of patients with immune mediated diseases. We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function and fate coupled to a biomarker discovery effort with potential to bring precision to the treatment of immune-mediated diseases. Launched in 2018 by Third Rock Ventures with a $60 million Series A financing, Rheos is built on groundbreaking science from pioneers in the field, our passionate team of more than 35 employees is advancing a novel pipeline of immunometabolism drugs, and in December 2019, we entered into a worldwide collaboration with Roche to identify and develop new therapeutics for autoimmune and inflammatory disease. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced leadership team that integrates immunology, metabolism, computational biology, and drug discovery to unlock a new frontier in precision medicine for immune mediated disease.

  • Original language

    Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop a novel class of medicines with potential to transform the lives of patients with immune mediated diseases. We are rapidly applying a first-in-field approach in immunometabolism with a comprehensive, systems-biology understanding of the metabolic pathways that drive immune cell function and fate coupled to a biomarker discovery effort with potential to bring precision to the treatment of immune-mediated diseases. Launched in 2018 by Third Rock Ventures with a $60 million Series A financing, Rheos is built on groundbreaking science from pioneers in the field, our passionate team of more than 35 employees is advancing a novel pipeline of immunometabolism drugs, and in December 2019, we entered into a worldwide collaboration with Roche to identify and develop new therapeutics for autoimmune and inflammatory disease. We have brought together leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced leadership team that integrates immunology, metabolism, computational biology, and drug discovery to unlock a new frontier in precision medicine for immune mediated disease.

  • SIAP46: Join Now Bonus Jackpot Situs Gacor Indonesia 46 Game Maxwin

    Situs SIAP46 sekarang dapat join daftar langsung dapat bonus jackpot dari 46 games gampang maxwin di Indonesia tahun 2024 promo untuk hari ini saja.

  • https://www.s20.org/
Corporate interactions BETA
Corporate TypeTweets Articles
Roche
Roche
Pharmaceutical, Biotechnology, Biotechnology Research
Roche
Pharmaceutical, Biotechnology, Biotechnology Research
Not capitalistic
Partnership
Not event

19 Dec 2019


Similar entities
Loading...
Loading...
Social network dynamics